The Indonesian Journal of Infectious Diseases最新文献_第3页

Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. 2019年冠状病毒后疾病（COVID-19）状况或长COVID的全球患病率：荟萃分析和系统评价

The Indonesian Journal of Infectious Diseases Pub Date : 2022-11-01 DOI: 10.1093/infdis/jiac136

Chen Chen, Spencer R Haupert, Lauren Zimmermann, Xu Shi, Lars G Fritsche, Bhramar Mukherjee

{"title":"Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review.","authors":"Chen Chen, Spencer R Haupert, Lauren Zimmermann, Xu Shi, Lars G Fritsche, Bhramar Mukherjee","doi":"10.1093/infdis/jiac136","DOIUrl":"10.1093/infdis/jiac136","url":null,"abstract":"Background: This study aims to examine the worldwide prevalence of post-coronavirus disease 2019 (COVID-19) condition, through a systematic review and meta-analysis.Methods: PubMed, Embase, and iSearch were searched on July 5, 2021 with verification extending to March 13, 2022. Using a random-effects framework with DerSimonian-Laird estimator, we meta-analyzed post-COVID-19 condition prevalence at 28+ days from infection.Results: Fifty studies were included, and 41 were meta-analyzed. Global estimated pooled prevalence of post-COVID-19 condition was 0.43 (95% confidence interval [CI], .39-.46). Hospitalized and nonhospitalized patients had estimates of 0.54 (95% CI, .44-.63) and 0.34 (95% CI, .25-.46), respectively. Regional prevalence estimates were Asia (0.51; 95% CI, .37-.65), Europe (0.44; 95% CI, .32-.56), and United States of America (0.31; 95% CI, .21-.43). Global prevalence for 30, 60, 90, and 120 days after infection were estimated to be 0.37 (95% CI, .26-.49), 0.25 (95% CI, .15-.38), 0.32 (95% CI, .14-.57), and 0.49 (95% CI, .40-.59), respectively. Fatigue was the most common symptom reported with a prevalence of 0.23 (95% CI, .17-.30), followed by memory problems (0.14; 95% CI, .10-.19).Conclusions: This study finds post-COVID-19 condition prevalence is substantial; the health effects of COVID-19 seem to be prolonged and can exert stress on the healthcare system.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"186 1","pages":"1593-1607"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74175250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polio by the Numbers-A Global Perspective. 小儿麻痹症的数字-全球视角。

The Indonesian Journal of Infectious Diseases Pub Date : 2022-10-17 DOI: 10.1093/infdis/jiac130

Kamran Badizadegan, Dominika A Kalkowska, Kimberly M Thompson

{"title":"Polio by the Numbers-A Global Perspective.","authors":"Kamran Badizadegan, Dominika A Kalkowska, Kimberly M Thompson","doi":"10.1093/infdis/jiac130","DOIUrl":"10.1093/infdis/jiac130","url":null,"abstract":"Background: Investments in national immunization programs and the Global Polio Eradication Initiative (GPEI) have resulted in substantial reductions in paralytic polio worldwide. However, cases prevented because of investments in immunization programs and GPEI remain incompletely characterized.Methods: Using a global model that integrates polio transmission, immunity, and vaccine dynamics, we provide estimates of polio incidence and numbers of paralytic cases prevented. We compare the results with reported cases and estimates historically published by the World Health Organization.Results: We estimate that the existence and use of polio vaccines prevented 5 million cases of paralytic polio for 1960-1987 and 24 million cases worldwide for 1988-2021 compared to a counterfactual world with no polio vaccines. Since the 1988 resolution to eradicate polio, our estimates suggest GPEI prevented 2.5-6 million cases of paralytic polio compared to counterfactual worlds without GPEI that assume different levels of intensity of polio vaccine use in routine immunization programs.Conclusions: Analysis of historical cases provides important context for understanding and communicating the benefits of investments made in polio eradication. Prospective studies will need to explore the expected benefits of future investments, the outcomes of which will depend on whether and when polio is globally eradicated.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"44 1","pages":"1309-1318"},"PeriodicalIF":0.0,"publicationDate":"2022-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81286799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Population-level relative effectiveness of the COVID-19 vaccines and the contribution of naturally acquired immunity COVID-19疫苗的人群水平相对有效性和自然获得性免疫的贡献

The Indonesian Journal of Infectious Diseases Pub Date : 2022-10-04 DOI: 10.1101/2022.10.04.22280689

Kayoko Shioda, Yang-ling Chen, M. Collins, B. Lopman

{"title":"Population-level relative effectiveness of the COVID-19 vaccines and the contribution of naturally acquired immunity","authors":"Kayoko Shioda, Yang-ling Chen, M. Collins, B. Lopman","doi":"10.1101/2022.10.04.22280689","DOIUrl":"https://doi.org/10.1101/2022.10.04.22280689","url":null,"abstract":"Background: Immune protection against SARS-CoV-2 can be induced by natural infection or vaccination or both. The interaction between vaccine-induced immunity and naturally acquired immunity at the population level has been understudied. Methods: We used regression models to evaluate whether the impact of COVID-19 vaccines differed across states with different levels of naturally acquired immunity from March 2021 to April 2022 in the United States. Analysis was conducted for three evaluation periods separately (Alpha, Delta, and Omicron waves). As a proxy of the proportion of the population with naturally acquired immunity, we used either the reported seroprevalence or the estimated proportion of the population ever infected in each state. Results: COVID-19 mortality decreased as the coverage of [≥]1 dose increased among people [≥]65 years of age, and this effect did not vary by seroprevalence or the proportion of the total population ever infected. Seroprevalence and the proportion ever infected were not associated with COVID-19 mortality, after controlling for vaccine coverage. These findings were consistent in all evaluation periods. Conclusions: COVID-19 vaccination was associated with a sustained reduction in mortality at the state level during the Alpha, Delta, and Omicron periods. The effect did not vary by naturally acquired immunity.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85878022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Effectiveness and Duration of Protection of a Fourth Dose of COVID-19 mRNA Vaccine among Long-Term Care Residents in Ontario, Canada 加拿大安大略省长期护理居民第四剂COVID-19 mRNA疫苗的有效性和保护时间

The Indonesian Journal of Infectious Diseases Pub Date : 2022-09-30 DOI: 10.1101/2022.09.29.22280526

R. Grewal, Leann Nguyen, S. Buchan, S. Wilson, Andrew P Costa, Jeffrey C Kwong

{"title":"Effectiveness and Duration of Protection of a Fourth Dose of COVID-19 mRNA Vaccine among Long-Term Care Residents in Ontario, Canada","authors":"R. Grewal, Leann Nguyen, S. Buchan, S. Wilson, Andrew P Costa, Jeffrey C Kwong","doi":"10.1101/2022.09.29.22280526","DOIUrl":"https://doi.org/10.1101/2022.09.29.22280526","url":null,"abstract":"Background: As of December 30, 2021, Ontario long-term care (LTC) residents who received a third dose of COVID-19 vaccine [≥]84 days previously were offered a fourth dose to prevent a surge in COVID-19-related morbidity and mortality due to the Omicron variant. Seven months have passed since fourth doses were implemented, allowing for the examination of fourth dose protection over time. Methods: We used a test-negative design and linked databases to estimate the marginal effectiveness (4 versus 3 doses) and vaccine effectiveness (VE; 2, 3, or 4 doses versus no doses) of mRNA vaccines among Ontario LTC residents aged [≥]60 years who were tested for SARS-CoV-2 between December 30, 2021 and August 3, 2022. Outcome measures included any Omicron infection, symptomatic infection, and severe outcomes (hospitalization or death). Results: We included 21,275 Omicron cases and 273,466 test-negative controls. The marginal effectiveness of a fourth dose <84 days ago compared to a third dose received [≥]84 days ago was 23% (95% Confidence Interval [CI] 17-29%), 36% (95%CI 26-44%), and 37% (95%CI 24-48%) against SARS-CoV-2 infection, symptomatic infection, and severe outcomes, respectively. Additional protection provided by a fourth dose compared to a third dose was negligible against all outcomes [≥]168 days after vaccination. Compared to unvaccinated individuals, vaccine effectiveness (VE) of a fourth dose decreased from 49% (95%CI 44%-54%) to 18% (95%CI 5-28%) against infection, 69% (95%CI 62-75%) to 44% (95%CI 24-59%) against symptomatic infection, and 82% (95%CI 77-86%) to 74% (95%CI 62-82%) against severe outcomes <84 days versus [≥]168 days after vaccination. Conclusions: Our findings suggest that fourth doses of mRNA COVID-19 vaccines provide additional protection against Omicron-related outcomes in LTC residents, but the protection wanes over time, with more waning seen against infection than severe outcomes.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90573292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

In Elimination Settings, Measles Antibodies Wane After Vaccination but Not After Infection: A Systematic Review and Meta-Analysis. 在消除环境中，麻疹抗体在接种疫苗后减弱，但在感染后不会减弱：一项系统综述和荟萃分析。

The Indonesian Journal of Infectious Diseases Pub Date : 2022-09-28 DOI: 10.1093/infdis/jiac039

Shelly Bolotin, Selma Osman, Stephanie L Hughes, Archchun Ariyarajah, Andrea C Tricco, Sumaiya Khan, Lennon Li, Caitlin Johnson, Lindsay Friedman, Nazish Gul, Rachel Jardine, Maryrose Faulkner, Susan J M Hahné, Jane M Heffernan, Alya Dabbagh, Paul A Rota, Alberto Severini, Mark Jit, David N Durrheim, Walter A Orenstein, William J Moss, Sebastian Funk, Nikki Turner, William Schluter, Jaleela S Jawad, Natasha S Crowcroft

{"title":"In Elimination Settings, Measles Antibodies Wane After Vaccination but Not After Infection: A Systematic Review and Meta-Analysis.","authors":"Shelly Bolotin, Selma Osman, Stephanie L Hughes, Archchun Ariyarajah, Andrea C Tricco, Sumaiya Khan, Lennon Li, Caitlin Johnson, Lindsay Friedman, Nazish Gul, Rachel Jardine, Maryrose Faulkner, Susan J M Hahné, Jane M Heffernan, Alya Dabbagh, Paul A Rota, Alberto Severini, Mark Jit, David N Durrheim, Walter A Orenstein, William J Moss, Sebastian Funk, Nikki Turner, William Schluter, Jaleela S Jawad, Natasha S Crowcroft","doi":"10.1093/infdis/jiac039","DOIUrl":"10.1093/infdis/jiac039","url":null,"abstract":"Background: We conducted a systematic review to assess whether measles humoral immunity wanes in previously infected or vaccinated populations in measles elimination settings.Methods: After screening 16 822 citations, we identified 9 articles from populations exposed to wild-type measles and 16 articles from vaccinated populations that met our inclusion criteria.Results: Using linear regression, we found that geometric mean titers (GMTs) decreased significantly in individuals who received 2 doses of measles-containing vaccine (MCV) by 121.8 mIU/mL (95% confidence interval [CI], -212.4 to -31.1) per year since vaccination over 1 to 5 years, 53.7 mIU/mL (95% CI, -95.3 to -12.2) 5 to 10 years, 33.2 mIU/mL (95% CI, -62.6 to -3.9), 10 to 15 years, and 24.1 mIU/mL (95% CI, -51.5 to 3.3) 15 to 20 years since vaccination. Decreases in GMT over time were not significant after 1 dose of MCV or after infection. Decreases in the proportion of seropositive individuals over time were not significant after 1 or 2 doses of MCV or after infection.Conclusions: Measles antibody waning in vaccinated populations should be considered in planning for measles elimination.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"62 1","pages":"1127-1139"},"PeriodicalIF":0.0,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81262896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Interplay Between Replication Capacity of HIV-1 and Surrogate Markers of Disease. HIV-1复制能力与疾病替代标志物之间的相互作用。

The Indonesian Journal of Infectious Diseases Pub Date : 2022-09-21 DOI: 10.1093/infdis/jiac100

Audrey E Rindler, Katharina Kusejko, Herbert Kuster, Kathrin Neumann, Christine Leemann, Marius Zeeb, Sandra E Chaudron, Dominique L Braun, Roger D Kouyos, Karin J Metzner, Huldrych F Günthard

{"title":"The Interplay Between Replication Capacity of HIV-1 and Surrogate Markers of Disease.","authors":"Audrey E Rindler, Katharina Kusejko, Herbert Kuster, Kathrin Neumann, Christine Leemann, Marius Zeeb, Sandra E Chaudron, Dominique L Braun, Roger D Kouyos, Karin J Metzner, Huldrych F Günthard","doi":"10.1093/infdis/jiac100","DOIUrl":"10.1093/infdis/jiac100","url":null,"abstract":"Background: HIV-1 replication capacity (RC) of transmitted/founder viruses may influence the further course of HIV-1 infection.Methods: RCs of 355 whole-genome primary HIV-1 isolates derived from samples acquired during acute and recent primary HIV-1 infection (PHI) were determined using a novel high-throughput infection assay in primary cells. The RCs were used to elucidate potential factors that could be associated with RC during PHI.Results: Increased RC was found to be associated with increased set point viral load (VL), and significant differences in RCs among 13 different HIV-1 subtypes were discerned. Notably, we observed an increase in RCs for primary HIV-1 isolates of HIV-1 subtype B over a 17-year period. Associations were not observed between RC and CD4 count at sample date of RC measurement, CD4 recovery after initiation of antiretroviral treatment, CD4 decline in untreated individuals, and acute retroviral syndrome severity scores.Conclusions: These findings highlight that RCs of primary HIV-1 isolates acquired during the acute and recent phase of infection are more associated with viral factors, that is set point VL, than with host factors. Furthermore, we observed a temporal increase in RC for HIV-1 subtype B viruses over a period of 17 years.Clinical trials registration: NCT00537966.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"27 1","pages":"1057-1068"},"PeriodicalIF":0.0,"publicationDate":"2022-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89897645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Elevated Plasma Matrix Metalloproteinase 8 Associates With Sputum Culture Positivity in Pulmonary Tuberculosis. 肺结核患者血浆基质金属蛋白酶8升高与痰培养阳性相关。

The Indonesian Journal of Infectious Diseases Pub Date : 2022-09-13 DOI: 10.1093/infdis/jiac160

N F Walker, F Karim, M Y S Moosa, S Moodley, M Mazibuko, K Khan, T R Sterling, Y F van der Heijden, A D Grant, P T Elkington, A Pym, A Leslie

引用次数: 0

Amplicon Sequencing as a Potential Surveillance Tool for Complexity of Infection and Drug Resistance Markers in Plasmodium falciparum Asymptomatic Infections. 扩增子测序作为恶性疟原虫无症状感染感染复杂性和耐药标志物的潜在监测工具。

The Indonesian Journal of Infectious Diseases Pub Date : 2022-09-13 DOI: 10.1093/infdis/jiac144

Kevin Wamae, Kelvin M Kimenyi, Victor Osoti, Zaydah R de Laurent, Leonard Ndwiga, Oksana Kharabora, Nicholas J Hathaway, Jeffrey A Bailey, Jonathan J Juliano, Philip Bejon, Lynette Isabella Ochola-Oyier

{"title":"Amplicon Sequencing as a Potential Surveillance Tool for Complexity of Infection and Drug Resistance Markers in Plasmodium falciparum Asymptomatic Infections.","authors":"Kevin Wamae, Kelvin M Kimenyi, Victor Osoti, Zaydah R de Laurent, Leonard Ndwiga, Oksana Kharabora, Nicholas J Hathaway, Jeffrey A Bailey, Jonathan J Juliano, Philip Bejon, Lynette Isabella Ochola-Oyier","doi":"10.1093/infdis/jiac144","DOIUrl":"10.1093/infdis/jiac144","url":null,"abstract":"Background: Genotyping Plasmodium falciparum subpopulations in malaria infections is an important aspect of malaria molecular epidemiology to understand within-host diversity and the frequency of drug resistance markers.Methods: We characterized P. falciparum genetic diversity in asymptomatic infections and subsequent first febrile infections using amplicon sequencing (AmpSeq) of ama1 in Coastal Kenya. We also examined temporal changes in haplotype frequencies of mdr1, a drug-resistant marker.Results: We found >60% of the infections were polyclonal (complexity of infection [COI] >1) and there was a reduction in COI over time. Asymptomatic infections had a significantly higher mean COI than febrile infections based on ama1 sequences (2.7 [95% confidence interval {CI}, 2.65-2.77] vs 2.22 [95% CI, 2.17-2.29], respectively). Moreover, an analysis of 30 paired asymptomatic and first febrile infections revealed that many first febrile infections (91%) were due to the presence of new ama1 haplotypes. The mdr1-YY haplotype, associated with chloroquine and amodiaquine resistance, decreased over time, while the NY (wild type) and the NF (modulates response to lumefantrine) haplotypes increased.Conclusions: This study emphasizes the utility of AmpSeq in characterizing parasite diversity as it can determine relative proportions of clones and detect minority clones. The usefulness of AmpSeq in antimalarial drug resistance surveillance is also highlighted.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"38 1","pages":"920-927"},"PeriodicalIF":0.0,"publicationDate":"2022-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86505482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Functional Compartmentalization of Antibodies in the Central Nervous System During Chronic HIV Infection. 慢性HIV感染期间中枢神经系统抗体的功能区隔化。

The Indonesian Journal of Infectious Diseases Pub Date : 2022-09-04 DOI: 10.1093/infdis/jiac138

Marianna Spatola, Carolin Loos, Deniz Cizmeci, Nicholas Webb, Matthew J Gorman, Evan Rossignol, Sally Shin, Dansu Yuan, Laura Fontana, Shibani S Mukerji, Douglas A Lauffenburger, Dana Gabuzda, Galit Alter

{"title":"Functional Compartmentalization of Antibodies in the Central Nervous System During Chronic HIV Infection.","authors":"Marianna Spatola, Carolin Loos, Deniz Cizmeci, Nicholas Webb, Matthew J Gorman, Evan Rossignol, Sally Shin, Dansu Yuan, Laura Fontana, Shibani S Mukerji, Douglas A Lauffenburger, Dana Gabuzda, Galit Alter","doi":"10.1093/infdis/jiac138","DOIUrl":"10.1093/infdis/jiac138","url":null,"abstract":"The central nervous system (CNS) has emerged as a critical HIV reservoir. Thus, interventions aimed at controlling and eliminating HIV must include CNS-targeted strategies. Given the inaccessibility of the brain, efforts have focused on cerebrospinal fluid (CSF), aimed at defining biomarkers of HIV-disease in the CNS, including HIV-specific antibodies. However, how antibodies traffic between the blood and CNS, and whether specific antibody profiles track with HIV-associated neurocognitive disorders (HAND) remains unclear. Here, we comprehensively profiled HIV-specific antibodies across plasma and CSF from 20 antiretroviral therapy (ART) naive or treated persons with HIV. CSF was populated by IgG1 and IgG3 antibodies, with reduced Fc-effector profiles. While ART improved plasma antibody functional coordination, CSF profiles were unaffected by ART and were unrelated to HAND severity. These data point to a functional sieving of antibodies across the blood-brain barrier, providing previously unappreciated insights for the development of next-generation therapeutics targeting the CNS reservoir.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"24 1","pages":"738-750"},"PeriodicalIF":0.0,"publicationDate":"2022-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74793535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plasmodium falciparum in Aotus nancymaae: A New Model for Placental Malaria. 南毛猴恶性疟原虫：一种新的胎盘疟疾模型。

The Indonesian Journal of Infectious Diseases Pub Date : 2022-08-26 DOI: 10.1093/infdis/jiac096

Ankur Sharma, Bethany Jenkins, Adovi Akue, Lynn E Lambert, Sachy Orr-Gonzalez, Marvin L Thomas, Almahamoudou Mahamar, Bacary S Diarra, Alassane Dicko, Michal Fried, Patrick E Duffy

{"title":"Plasmodium falciparum in Aotus nancymaae: A New Model for Placental Malaria.","authors":"Ankur Sharma, Bethany Jenkins, Adovi Akue, Lynn E Lambert, Sachy Orr-Gonzalez, Marvin L Thomas, Almahamoudou Mahamar, Bacary S Diarra, Alassane Dicko, Michal Fried, Patrick E Duffy","doi":"10.1093/infdis/jiac096","DOIUrl":"10.1093/infdis/jiac096","url":null,"abstract":"Plasmodium falciparum-infected erythrocytes that display the variant surface antigen VAR2CSA bind chondroitin sulfate A (CSA) to sequester in placental intervillous spaces, causing severe sequelae for mother and offspring. Here, we establish a placental malaria (PM) monkey model. Pregnant Aotus infected with CSA-binding P. falciparum CS2 parasites during the third trimester developed pronounced sequestration of late-stage parasites in placental intervillous spaces that express VAR2CSA and bind specifically to CSA. Similar to immune multigravid women, a monkey infected with P. falciparum CS2 parasites over successive pregnancies acquired antibodies against VAR2CSA, with potent functional activity that was boosted upon subsequent pregnancy infections. Aotus also developed functional antibodies after multiple acute PM episodes and subsequent VAR2CSA immunization. In summary, P. falciparum infections in pregnant Aotus monkeys recapitulate all the prominent features of human PM infection and immunity, and this model can be useful for basic mechanistic studies and preclinical studies to qualify candidate PM vaccines. Clinical Trials Registration: NCT02471378.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"8 1","pages":"521-527"},"PeriodicalIF":0.0,"publicationDate":"2022-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9417121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80235033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0